1 |
Ardizzoni A, Boni L, Tiseo M, et al (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99, 847-57.
DOI
|
2 |
Cheng J, Ha M, Wang Y, et al (2012). A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 231-8.
DOI
|
3 |
Ettinger DS, Akerley W, Borghaei H, et al (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10, 1236-71.
DOI
|
4 |
Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev, 33, 565-77.
DOI
|
5 |
Li F, Sun X, Sun N, et al (2010). Association Between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol, 33, 489-94.
DOI
|
6 |
Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
|
7 |
Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
DOI
|
8 |
Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23.
DOI
|
9 |
Spiro SG, Silvestri GA (2005). The treatment of advanced nonsmall cell lung cancer. Curr Opin Pulm Med, 11, 287-91.
DOI
|
10 |
Su D, Ma S, Liu P, et al (2007). Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 56, 281-8.
DOI
|
11 |
Yu Q, Han J, Pan J (2007). The relationship between the polymorphisms of gene XGP and MDR1 and the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy. Practical J Cancer, 22, 252-6.
|